Browsing Breast Cancer Research by title
Now showing items 374-393 of 666
-
Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development.
(2019-01)Cellular models for siRNA and small molecule high-throughput screening have been widely used in the last decade to identify targets for drug discovery. As an example, we present a twofold readout approach based on cell ... -
Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions.
(ELIFE SCIENCES PUBLICATIONS LTD, 2020-05-28)Genetic interactions, including synthetic lethal effects, can now be systematically identified in cancer cell lines using high-throughput genetic perturbation screens. Despite this advance, few genetic interactions have ... -
INTEND II randomized clinical trial of intraoperative duct endoscopy in pathological nipple discharge.
(WILEY, 2018-11-01)BACKGROUND: The majority of lesions resulting in pathological nipple discharge are benign. Conventional surgery is undirected and targeting the causative lesion by duct endoscopy may enable more accurate surgery with fewer ... -
International Survey on Frailty Assessment in Patients with Cancer.
(OXFORD UNIV PRESS, 2022-10-01)BACKGROUND: Frailty negatively affects the outcomes of patients with cancer, and its assessment might vary widely in the real world. The objective of this study was to explore awareness and use of frailty screening tools ... -
Interplay between base excision repair protein XRCC1 and ALDH2 predicts overall survival in lung and liver cancer patients.
(SPRINGER, 2018-10-01)BACKGROUND: To deliver efficacious personalised cancer treatment, it is essential to characterise the cellular metabolism as well as the genetic stability of individual tumours. In this study, we describe a new axis between ... -
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.
(BMC, 2015-05-22)BACKGROUND: HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and predictive marker of response to anti-HER2 agents. In a subset of these cases, heterogeneous ... -
Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions.
(WILEY, 2019-03-01)Estrogen receptor α-positive (ER-positive) or 'luminal' breast cancers were notoriously difficult to establish as patient-derived xenografts (PDXs). We and others recently demonstrated that the microenvironment is critical ... -
Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1.
(WILEY, 2021-03-05)Invasive lobular carcinoma (ILC) is the most frequent special histological subtype of breast cancer, typically characterized by loss of E-cadherin. It has clinical features distinct from other estrogen receptor-positive ... -
Investigating a range of late effects of Hodgkin lymphoma treatments
(Institute of Cancer Research (University Of London), 2021-01-31)Dramatic improvement in Hodgkin lymphoma (HL) survival rates over recent decades has come at significant cost: treatment-related late effects which are epitomised in female HL patients treated at young ages. The aims of ... -
Investigation of combination treatments using radiotherapy and stimulators of nucleic-acid sensing immune pathways in an organoid model of basal-like breast cancer
(Institute of Cancer Research (University Of London), 2022-10-12)The majority of triple-negative breast cancers (TNBC) are of the basal-like subtype, which has a poorer prognosis than non-basal TNBC. Few targeted therapies are approved for TNBC, and although immune checkpoint inhibitors ... -
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
(SPRINGER, 2021-12-03)PURPOSE: PI3K/AKT pathway alterations are frequent in hormone receptor-positive (HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib-paclitaxel in PI3K pathway-mutant HR+ unresectable locally advanced/metastatic ... -
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
(2017-04)Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 ... -
Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology.
(ELSEVIER SCIENCE BV, 2018-09-01)UNLABELLED: Testicular germ cell tumour (TGCT) is the most common cancer in young men. Multiplex TGCT families have been well reported and analyses of population cancer registries have demonstrated a four- to eightfold ... -
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
(NATURE PUBLISHING GROUP, 2013-04-01)Breast cancer is the most common cancer among women. Common variants at 27 loci have been identified as associated with susceptibility to breast cancer, and these account for ∼9% of the familial risk of the disease. We ... -
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.
(CELL PRESS, 2016-03-15)One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase ... -
Late recurrence in ER+ breast cancer - refining risk prediction beyond 5 years
(Institute of Cancer Research (University Of London), 2021-11-30)ER positive (ER+) breast cancer has the potential to recur many years following diagnosis. Predicting who is most at risk of recurrence and when this may occur is complex. Risk prediction incorporates clinical, pathological ... -
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
(AMER ASSOC CANCER RESEARCH, 2023-06-02)UNLABELLED: Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient ... -
Length of FMR1 repeat alleles within the normal range does not substantially affect the risk of early menopause.
(OXFORD UNIV PRESS, 2016-10-01)STUDY QUESTION: Is the length of FMR1 repeat alleles within the normal range associated with the risk of early menopause? SUMMARY ANSWER: The length of repeat alleles within the normal range does not substantially affect ...